At PEGS EU 2021, Abveris CEO Tracey Mullen shared a few important lessons learned through using the Beacon system for antibody discovery. She discussed how the Berkeley Lights Platform has enabled Abveris to focus on deeply screening their antibodies upstream and only pulling forward the most qualified and functionally relevant antibodies for re-expression.
Berkeley Lights and ChemPartner provide a case study in accelerated discovery of unique Anti-PD-L1 antibodies from spleen versus bone marrow of immunized mice, via single plasma B cell cloning on the Beacon platform.
Find out how Opto™ Plasma B Discovery on the Beacon optofluidic system allows CROs to scale their business and rapidly deliver lead molecules even against difficult targets.
This poster developed by Berkeley Lights and Pfizer demonstrates rapid antibody discovery on the Beacon platform, showing how it can rapidly isolate and screen thousands of primary ASCs in a single day.